Pathophysiology of cytotoxic drug-induced emesis: far from crystal-clear

[1]  P. Schein,et al.  Gastrointestinal toxicity of chemotherapeutic agents. , 2006, Seminars in oncology.

[2]  L. Cubeddu,et al.  Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. , 1990, The New England journal of medicine.

[3]  R. Leslie,et al.  Localization of 5-HT3 receptor binding sites in human dorsal vagal complex. , 1989, European journal of pharmacology.

[4]  Steven M. Grunberg.  Oh, what a tangled web. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Higgins,et al.  5‐HT3 receptor antagonists injected into the area postrema inhibit cisplatin‐induced emesis in the ferret , 1989, British journal of pharmacology.

[6]  M. Kr,et al.  Recent advances in the management of nausea and vomiting caused by antineoplastic agents. , 1989 .

[7]  C. M. Edwards,et al.  Chemotherapy Induced Emesis – Mechanisms and Treatment: A Review , 1988, Journal of the Royal Society of Medicine.

[8]  G. Sanger,et al.  Neuropharmacology of emesis induced by anti-cancer therapy. , 1988, Trends in pharmacological sciences.

[9]  R. Bolaños,et al.  Perforation of the hypopharynx: demonstration by computerized tomography. , 1988, Southern medical journal.

[10]  J. Lévy,et al.  CASE DEFINITIONS FOR PAEDIATRIC AIDS APPLIED TO AFRICAN CHILDREN SEEN IN BELGIUM , 1988, The Lancet.

[11]  B. Costall,et al.  Effects of the 5‐HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain , 1987, British journal of pharmacology.

[12]  G. Sanger,et al.  Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis. , 1987, British Journal of Cancer.

[13]  B. Costall,et al.  5-hydroxytryptamine m-receptor antagonism to prevent cisplatin-induced emesis , 1986, Neuropharmacology.

[14]  J. Grashuis,et al.  Electrogastrographic study of gastric myoelectrical activity in patients with unexplained nausea and vomiting. , 1986, Gut.

[15]  R. Leslie.  Comparative aspects of the area postrema: fine-structural considerations help to determine its function , 1986, Cellular and Molecular Neurobiology.

[16]  S. Gaffin,et al.  RADIOTHERAPY, ENDOTOXAEMIA, AND NAUSEA , 1986, The Lancet.

[17]  J. Smyth,et al.  Small intestinal mucosal toxicity of cis-platinum--comparison of toxicity with platinum analogues and dexamethasone. , 1986, British Journal of Cancer.

[18]  G. Morrow,et al.  The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy , 1985, Cancer.

[19]  N. W. Pedigo,et al.  Muscarinic cholinergic receptors in area postrema and brainstem areas regulating emesis , 1985, Brain Research Bulletin.

[20]  H. Borison,et al.  Role of the area postrema in vomiting and related functions. , 1984, Federation proceedings.

[21]  N. Strominger,et al.  Behavioral and electrophysiological studies of peptide-induced emesis in dogs. , 1984, Federation proceedings.

[22]  Borison Hl,et al.  Cisplatin-induced vomiting eliminated by ablation of the area postrema in cats. , 1984 .

[23]  Alan D. Miller,et al.  ‘Vomiting center’ reanalyzed: an electrical stimulation study , 1983, Brain Research.

[24]  A. Harris,et al.  CYTOTOXIC-THERAPY-INDUCED VOMITING IS MEDIATED VIA ENKEPHALIN PATHWAYS , 1982, The Lancet.

[25]  S. Peroutka,et al.  ANTIEMETICS: NEUROTRANSMITTER RECEPTOR BINDING PREDICTS THERAPEUTIC ACTIONS , 1982, The Lancet.

[26]  Y. Clement‐Cormier,et al.  Detection of dopamine receptors in the area postrema. , 1981, European journal of pharmacology.

[27]  R. Barton.  SHORT PRACTICE OF CLINICAL PSYCHIATRY , 1975, The Lancet.

[28]  K. Brizzee,et al.  Relief of intractable vomiting from surgical lesions in the area postrema. , 1962, Journal of neurosurgery.

[29]  H. L. Borison,et al.  Physiology and pharmacology of vomiting. , 1953, Pharmacological reviews.

[30]  S. Peroutka,et al.  Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors , 2004, Cancer Chemotherapy and Pharmacology.

[31]  S. Peroutka.  Chemotherapeutic agents do not interact with neurotransmitter receptors , 2004, Cancer Chemotherapy and Pharmacology.

[32]  K. Buchheit,et al.  5-HT 3 Receptors in the Gastrointestinal Tract , 1989 .

[33]  B. Richardson,et al.  Classification of 5-HT Receptors and Binding Sites: An Overview , 1989 .

[34]  B. Costall,et al.  5-HT3 Receptors in the Central Nervous System , 1989 .

[35]  P. Andrews,et al.  8 The neurophysiology of vomiting , 1988 .

[36]  R. Lefebvre,et al.  Peripheral Nervous Pathways Involved in Nausea and Vomiting , 1986 .

[37]  Y. Agid,et al.  Neurochemical Investigations into the Human Area Postrema , 1986 .

[38]  C. J. Davis,et al.  The Organisation of Vomiting as a Protective Reflex , 1986 .

[39]  G. Sanger,et al.  Dopamine Antagonists as Anti-Emetics and as Stimulants of Gastric Motility , 1984 .

[40]  H. Borison,et al.  A 1983 neuropharmacologic perspective of space sickness. , 1983, Brain, behavior and evolution.